• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AskBio Appoints Clinical Ops Executives

    SpectrumX Partners With UK Contract Manufacturer

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    SpectrumX Partners With UK Contract Manufacturer

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Catalent to Acquire Metrics Contract Services for $475M
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    UPS to Acquire Healthcare Logistics Provider Bomi Group

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    West Pharmaceutical Makes Strategic Investment in Latch Medical

    “3 Key Trends” with James Park

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Behind Every Successful eCOA Solution is a Robust Scientific Strategy
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Qosina

    Societal CDMO

    Biosynth Carbosynth

    Kyongbo Pharmaceutical

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Qosina

    Societal CDMO

    Biosynth Carbosynth

    Kyongbo Pharmaceutical

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Pharma Year 2017 in Review

    CDMOs grow faster than the Pharma market.

    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Related CONTENT
    • Taros Chemicals GmbH & Co. KG
    • Samsung Biologics
    • Sekisui
    • The Future of Clinical Trials
    • Outsourcing the Manufacture of Clinical Trial APIs
    Christoph Bieri, Managing Partner, Kurmann Partners03.09.18
    Globally, deal activity in 2017 was at a comparable level to 2016, and significantly lower than in 2014 and 2015. We counted 323 transactions (2016: 345), with cumulative deal values of $120 billion (2016: $95bn). In comparison, in 2014 and 2015, there were 440 to 490 transactions with cumulative deal values of approximately $225 billion. We believe that the earlier years were exceptional, and that the 2016/2017 level likely reflects normal rather than subdued merger and acquisition (M&A) activity.

    While global transaction numbers remained stable, the pattern shifted. As shown in Figure 1 in the picture slides above, there were fewer acquisitions involving targets based in the U.S., but significantly greater activity from bidders in emerging markets, when compared to 2016.

    The end of a long courtship for Actelion
    The largest transaction in 2017 was J&J’s acquisition of Actelion for $30 billion (see Figure 2 in the slide), the Swiss-based specialist in pulmonary arterial hypertension (PAH), and Europe’s largest biotech company.

    Back in 2011, activist investor Eliott tried to push Actelion’s management to initiate a sale process, when the company was trading at around 45 CHF per share. In January 2017, after a long and very public courtship in the second half of 2016—with Sanofi stepping in and out of the process—J&J agreed to pay CHF 280 per share.

    The valuation is perceived as very high, corresponding to 12 times revenues and 30 times EBIT. But not only did Actelion’s founders, Jean-Paul and Martine Clozel, realize a very attractive price for their shareholders, they also managed to carve-out Actelion’s pipeline and R&D outside the PAH franchise indication into a new company, Idorsia. In June 2017, the new company was floated on the Swiss stock exchange, and at the end of 2017 already had a market capitalization of more than $3 billion.

    Without doubt, Actelion is one of the most successful biotech stories in Europe to date.

    Big bets on cancer
    A substantial amount of available M&A funds in the pharma industry is spent on so-called “pipeline deals,” when large Pharma companies acquire small innovators with development programs or innovative products. The substantial prices paid in these transactions are based on the expectation of future profits which quite often are elusive; the deals are veritable billion-dollar bets.

    And Pharma is betting on oncology. Gilead acquired Kite Pharma for $10 billion, just before the latter’s CAR-T cell therapy against a form of B-cell cancer was approved. In January, Takeda paid $5 billion for Ariad Pharmaceuticals to get Ariad’s blood cancer drug and its lung cancer drug candidate. In December, Novartis offered $3.7 billion to secure the rights for AAA’s endocrine cancer treatment. And just before the year-end, Roche purchased Ignyta for $1.8 billion to take on a program of drug candidates against specific solid tumors.

    Continuing consolidation among CMOs and CROs
    Interestingly, five of the transactions with deal values greater than $1 billion involved companies which provide services to the Pharma industry, rather than Pharma companies themselves.

    In the contract manufacturing organization (CMO) space, former serial acquirer Patheon was taken over by ThermoFisher, the provider of R&D technology and Pharma services, for $7 billion. In the same period, Lonza completed the acquisition of Capsugel (announced in 2016, not in Figure 2) for $5.5 billion.

    In 2016, the merger of IMS Health and Quintiles (now trading as IQVIA) created a company providing services from early-stage research through to commercialization. In 2017, INC and InVentiv Health followed suit in a merger valued around $4.6 billion, with the stated claim to become another “end-to-end” service provider for the industry.

    Private equity groups (PEGs) drove the shaping of the CMO and the contract research organization (CRO) industries. PEGs seem to have continued confidence in the sector, increasing the value of the single bets. The CROs PPD and Parexel and the CDMO AMRI were acquired in billion-dollar transactions, a clear sign that financial investors believe that more consolidation is coming, and that operational improvements can be achieved.

    Renewed deal activity in generics
    Three transactions announced in 2017 with deal values greater than $1 billion involved generic drug firms. Akorn was acquired for $4.8 billion by Fresenius Kabi. With the deal, Fresenius expanded its portfolio of generics from sterile injectables to other difficult-to-make formulations. The other large deal in the U.S. was Amneal’s acquisition of IMPAX, a deal which was seen as a defensive step to the evolving crisis in the generics market in the U.S.

    In Europe, STADA, one of Europe’s largest generic drugs providers, was bought out by a consortium of investors for $6 billion. The protracted and highly public transaction process involved some drama, including the involuntary departure of the CEO and CFO of STADA, and the alleged installation of electronic surveillance equipment in the car of the CEO.

    More deals expected after tax overhaul
    The end of 2017 brought a big tax overhaul in the U.S., and many financial advisors expect that this may lead to increased M&A activity involving U.S. companies as buyers, across all industries.

    Against this backdrop, some observers expect that large deals amongst originators may be on the rise in 2018, particularly as pipeline deals become scarcer. Both Novartis and Sanofi are said to be under pressure to do large acquisitions. BMS is perceived as a potential target, and AstraZeneca’s survival as an independent company is often questioned.

    Large deals building momentum in OTC
    In OTC, three large transactions seem to be building momentum: In October, Merck KGaA announced the intention to sell its OTC portfolio business, with revenues of €860 million, which is expected to fetch €1.8 billion to €2.7 billion. This divestment was expected since February, as the German company then announced the preparation of the organization for a separation.

    Shortly after Merck’s announcement, Pfizer announced that they are seeking a buyer for their consumer health business. With revenues of $3.4 billion and a purchase price of up to $15 billion, Pfizer’s proposed deal is much larger.

    There are few obvious buyers for the portfolios. In March, GSK will have to decide whether to buy out Novartis from their JV. Bayer is still digesting its huge acquisition of OTC products from Merck & Co, and Reckitt Benckiser—keen to expand its OTC business—may first have to do a lot of homework.

    CDMOs grow faster than the Pharma market
    As Pharma companies refine their business strategy and market focus, Pharma manufacturing also undergoes a fundamental change. More and more, large Pharma “originators” view manufacturing as a non-core activity, unless the products involve proprietary technology. This is a boost for contract development and manufacturing organizations (CDMOs), and one of the key drivers for the consolidation of this industry.

    CDMOs collectively generate approximately $40 billion in revenue, and the large players forecast a market growth of 5% to 6.5% per year over the next five years. Two growth drivers are stated: First, small innovators (“biotech”) do not want to commit capital to building manufacturing plants, but rather use CDMOs. Second, outsourcing by Big Pharma is expected to increase further, from an “outsourcing penetration” of 30% today to 40% in 2020. Following this rationale, we believe that the CDMO industry may expand even faster, given that growth of the Pharma industry as a whole is expected to be 5% to 7%.

    Interestingly, the largest CDMOs grow faster than the largest Pharma firms, as can be seen in Figure 3 in the slider. Each bubble in this graph represents one company, with its size proportional to the company’s revenues. The position on the horizontal axis reflects the company’s growth in the last three years, while the position on the vertical axis reflects the profitability (EBITDA margin). The higher rate of growth of CDMOs reflects on one hand the consolidation in the CDMO market, and on the other hand the growing trend towards outsourcing in the industry. For comparison, Figure 3 also contains some of the large CROs, which also grew substantially faster than the Pharma market.

    Big Pharma’s bias for large CDMOs drives consolidation
    Despite a considerable number of M&A transactions, the CDMO market remains very fragmented. The top five players generate approximately 15% of the $40 billion total, and there is a long tail of medium-sized and smaller CDMOs—we count at least 300 companies offering CDMO services.

    However, there is a strong bias by Big Pharma for large CDMOs: Big Pharma firms want few, long-term, reliable relationships, and favor large CDMOs, which also have the capacity and means to manage and cultivate complex niche technologies, over smaller ones. A similar “size affinity” exists between Pharma companies and CROs. 

    Consequently, the CDMO industry is in a phase of intense consolidation, comparable to the CRO industry three to five years ago. As shown in Figure 4 in the slider, between 2013 and 2017 there were 30 to 60 transactions annually with C(D)MOs and manufacturing units as targets. The number of transactions peaked in 2015, but while the number of transactions decreased in the last two years, the deal volume (the sum of all published deal values) increased, mainly due to the very large deals: Capsugel/Lonza and Patheon/Thermo Fisher.

    Platform builders and new entrants
    Two particular type of M&A actors drive deal activity. First, several CDMOs made serial acquisitions to expand their platform and reach. Figure 5 in the slider illustrates the acquisition timeline of Catalent, Recipharm and Patheon which have used M&A to build up sizeable manufacturing platforms. These players use M&A as part of their business model to complement their technology footprint, geographic reach, and client portfolio.

    Second, new entrants, attracted to the industry consolidation, being driven by fragmentation, growth and size bias. As mentioned above, private equity groups (PEGS) have played a strong role in building the CDMO industry—as well as for CROs—and last year again saw several transactions involving PEGs buying out CDMOs, most notably AMRI. In addition, firms in related industries such as Thermo Fisher, a lab instrument and consumables supplier, are attracted to the CDMO industry. Table 1 in the slider deck gives examples of recent acquisitions of CDMOs by strategic buyers and private equity groups.

    Biopharma contract manufacturing
    Manufacturing of biologicals, for example antibodies which are produced using very sensitive mammalian cell cultures, is highly complicated and requires large dedicated investments. Even some of the largest Pharma companies prefer to enter into strategic alliances with specialist CDMOs, rather than building manufacturing plants on their own, as exemplified by Sanofi’s €270 million alliance with Lonza announced in February 2017.

    Due to the high barriers to entry, the biopharmaceutical CMO market is an oligopoly in which Samsung Biologics, Lonza and Boehringer have the lion’s share. However, some large new players are seeking to muscle their way in: Japanese Asahi Glass acquired CMC Biologics at the end of 2016, and KBI, subsidiary of Japanese group JSR, acquired two companies to expand its biopharmaceutical contract manufacturing capabilities.

    Biopharmaceutical toll manufacturing and biosimilar development overlap, as the example of Samsung Biologics shows. This company offers contract manufacturing services and has developed several biosimilars, in partnership with large biotech companies. Samsung Biologics is also an example of a successful new entrant into the CDMO market—with anticipated volume of 362,000 liters for mammalian cell culture, it is currently the largest biopharmaceutical CDMO. The company went public in November 2016 and at the beginning of 2018 traded at a market capitalization of more than $24 billion.

    The beginning of Pharma-CMO alliances?
    Pharma companies have for many years been relying on the acquisition of, or in-licensing from, biotech companies for innovation. In 2011 McKinsey, a consultancy, suggested that like the automotive industry, other parts of the Pharma value chain may disintegrate, with few large brand-owners sourcing everything—from innovation to manufacturing—through a network of suppliers. Along these lines, in the first half of this decade, Big Pharma companies have entered into strategic alliances with CROs, establishing preferred relationships with few (two or three) CROs instead of deciding case by case (or trial by trial) with whom to work.

    The same may happen in manufacturing. The large CDMOs are big, stable, and broad enough to cover substantially all manufacturing needs of Big Pharma companies, perhaps apart from biopharmaceuticals which may be covered by specialist CDMOs. We believe this is one reason for Lonza’s acquisition of Capsugel—complementing existing technical capabilities and gaining scale. Similarly, Patheon becomes part of a large group under Thermo Fisher and hence may be viewed as an even more compelling potential partner for Big Pharma companies.

    Obviously, given the many technical and regulatory constraints, transformation of a manufacturing network takes much more time to implement than changing suppliers of services. However, the transfer of manufacturing units from Pharma company to its future CDMO, could accelerate the process—thus the future of the CDMO industry may resemble its beginnings in the mid-90s. 


    Christoph Bieri is managing partner with Kurmann Partners, a Swiss-based M&A boutique focused on mid-market transactions in the pharmaceutical and medtech industries and adjacent segments. Christoph has led numerous buy-side and sell-side international transac-tions concerning targets based in the Europe and North America.
    Related Searches
    • cro industry
    • Development
    • end-to-end
    • pipeline
    Suggested For You
    Taros Chemicals GmbH & Co. KG Taros Chemicals GmbH & Co. KG
    Samsung Biologics Samsung Biologics
    Sekisui Sekisui
    The Future of Clinical Trials The Future of Clinical Trials
    Outsourcing the Manufacture of Clinical Trial APIs Outsourcing the Manufacture of Clinical Trial APIs
    Choosing and Managing a CDMO Choosing and Managing a CDMO
    Modularity in Injectables Manufacturing Modularity in Injectables Manufacturing
    Sai Life Sciences Opens New Biology Facility in Hyperbad, India Sai Life Sciences Opens New Biology Facility in Hyperbad, India
    Stelis Biopharma Appoints Mark Womack as CEO Stelis Biopharma Appoints Mark Womack as CEO
    ImmunoGenesis Opens Research Lab, Adds Key Roles ImmunoGenesis Opens Research Lab, Adds Key Roles
    Covectra Enhances ATLAS Serialization Platform for Repackaging Covectra Enhances ATLAS Serialization Platform for Repackaging
    Drug Product Safety and Security Drug Product Safety and Security
    Idifarma Launches Accelerated Pathway for Complex Drugs Idifarma Launches Accelerated Pathway for Complex Drugs
    Driving Efficiencies in Today’s Complex Trials Driving Efficiencies in Today’s Complex Trials
    CanSino Biologics Gets OGYÉI GMP Certificate for COVID Vax CanSino Biologics Gets OGYÉI GMP Certificate for COVID Vax

    Related Buyers Guide Companies

    • Taros Chemicals GmbH & Co. KG

      ...
      Dimitrios Tzalis, Manager Executive Projects 12.07.21

    • Samsung Biologics

      Samsung Biologics

      ...
      Yeyoung Kim, Global PR Specialist 12.02.21

    • Sekisui

      ...
      Jim Alferman, Associate Director, Business Development 10.13.21


    • Clinical Trials
      The Future of Clinical Trials

      The Future of Clinical Trials

      Dr. Greg Licholai of ICON plc on key market trends, the future of clinical trials and the acquisition of PRA.
      Kristin Brooks, Managing Editor 09.09.21

    • APIs | Clinical Trial Materials
      Outsourcing the Manufacture of Clinical Trial APIs

      Outsourcing the Manufacture of Clinical Trial APIs

      What to consider when deciding to partner with a CDMO for manufacturing.
      Josh Hoerner, General Manager, Purisys 09.09.21

    Loading, Please Wait..
    Trending
    • Almac Invests $65M To Expand North American HQ
    • Just – Evotec Biologics And Alpine Immune Sciences Expand Partnership
    • West Pharmaceutical Makes Strategic Investment In Latch Medical
    • AskBio Appoints Clinical Ops Executives
    • Catalent To Acquire Metrics Contract Services For $475M
    Breaking News
    • AskBio Appoints Clinical Ops Executives
    • GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    • SpectrumX Partners With UK Contract Manufacturer
    • Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership
    • Almac Invests $65M to Expand North American HQ
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Aug. 13
    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    Consumers are Clamoring for Vintage Glam: Spate
    Kayali’s Lovefest Fragrance, Newell’s New Candle and HydraFacial’s Record Financial Results
    Self Care Trumps Home Care Post-Covid
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Aug. 13
    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login